Subverting the traditional treatment of NO cylinder
It is reported that “Norring Bio” has recently completed tens of millions of yuan in Series A financing. This round of financing was led by Northern Light Venture Capital, and the original investor, Nanjing Eagle Alliance, participated in the investment. The funds raised will be mainly used to advance the clinical trials of the company’s nitric oxide (NO)-related three types of medical device products.
“Norring Bio” was established in April 2018, mainly engaged in the research and development and production of new medical devices. The company’s core technology revolves around the occurrence and sustained release of nitric oxide and its use in the treatment of rare or difficult diseases such as asthma, diabetic foot, pulmonary fibrosis, and chronic obstructive pulmonary emphysema.Medical applications,Master the core technology independently, have multiple patents, AndIn-depth cooperation with the laboratory of the University of Michigan in the United States has obtained the University of Michigan’s exclusive authorization for related patents.
INOwill N100 and N200 (portable NO generator)
In recent years, NO gas treatment product technology has developed rapidly. During the epidemic, in March 2020 alone, two NO gas inhalation therapy company products were approved by the US FDA for emergency treatment of COVID-19. In addition, a total of 8 new indications for NO gas therapy are currently undergoing FDA registration and approval. However, the technology of NO gas treatment products is mostly concentrated in the United States. According to reports, “Nuo Ling Bio” is currently the only company in China that originally developed NO gas treatment.
The NO medical technology adopted by “Norring Bio” uses a unique portable electrochemical generation technology to realize the production and use of NO gas, has changed the traditional industrialized production preparation and re-medical transformation method. In application scenarios, this technology covers the combined use of ventilators from newborns to adults, realizing real-time monitoring of patient breathing patterns and ensuring the stability and safety of NO input. Recently,“Norring Creatures”The NO sensor technology is upgraded again to further ensure the accuracy and safety of NO treatment.
In terms of products, Dr. Mao Wen, CEO of “Noring Bio”, said that the company currently “Developed two NO generators“, among which “Portable NO The generator is the world’s first three-class medical device based on electrochemical chelation catalysis technology to generate NO gas in real time. It can be used independently or in conjunction with a variety of ventilators. The instrument is unique through precise raw material control and proportioning. The micro-release control reaction body produces high-purity NO gas. Noring’s technological innovation enables NO treatment to have the best cost performance, which is suitable for the future China’s medical price system.”
Aurora Ventures, the lead investor in this round, said: “Nitric oxide is the first endogenous gas molecule found to be involved in cell signaling. The relevant research of this scientist has won the Nobel Prize. The treatment of multiple indications of NO has been clinically applied in the United States for many years and has been included in relevant guidelines. There are also multiple indications in the progress of clinical research. The development and release of NO gas Innovation research has been ongoing.“
Editor: Cai Shuning